Clinical TrialMay 14, 2026, 06:11 AM
Onconetix Subsidiary Initiates U.S. Proclarix Study with Labcorp
AI Summary
Onconetix, Inc. announced Q1 2026 operational and clinical progress for its Swiss subsidiary, Proteomedix AG, developer of the Proclarix® diagnostic blood test. The update highlighted two new peer-reviewed publications reinforcing Proclarix's performance and prognostic value. Additionally, Proteomedix initiated the multi-center PRIME study with Labcorp Holdings Inc. in the U.S. to evaluate Proclarix, alongside continued European commercial expansion.
Key Highlights
- Onconetix's subsidiary, Proteomedix AG, reported Q1 2026 operational and clinical progress for Proclarix .
- Two new peer-reviewed papers reinforced Proclarix's performance in reducing overdiagnosis and unnecessary biopsies .
- The PRIME study, a multi-center clinical validation study, was initiated with Labcorp in the U.S .
- The PRIME study is designed to include up to 500 men to evaluate Proclarix across various ethnicities .
- Proclarix is a CE-IVD certified diagnostic blood test for clinically significant prostate cancer .
- European commercial expansion continued, with nearly 100 Proclarix tests in a UK screening initiative in Q1 2026 .
- A collaboration partner was identified in Turkey to expand market reach .
Price Impact
More from ONCO